Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013

Size: px
Start display at page:

Download "Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013"

Transcription

1 Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013

2 Conflicts CMO for The FH Foundation

3 Pre-talk quiz

4 What is cascade screening? 1. screening all family members 2. screening potentially affected family members 3. screening kids 69% 28% 4%

5 What is the goal LDL cholesterol for an FH patient? < 50% of pre-treatment LDL 100mg/dl 130mg/dl 60% 19% 22%

6 Mutations in 3 genes cause FH, what gene is not an FH gene? APOB LDLR PCSK9 LPA 12% 10% 57% 21%

7 DIAGNOSIS Familial Hypercholesterolemia

8 Can t find FH if you don t look! For adults > 20 yo: Suspect FH if LDL 190 mg/dl Average LDL in adult FH patients ~ 220 mg/dl FH more likely if FHx of premature coronary disease Look for physical exam findings of FH Xanthomas, xanthelasma, corneal arcus (< 45 yo) For children suspect FH if LDL 160 mg/dl

9

10 Formal Diagnostic criteria Three validated criteria MEDPED Dutch Lipid Clinic Network Simon Broome Register Once FH proband identified lower cut-offs for LDL should be used

11 Slide from MEDPED, courtesy of Dr. Hopkins

12 Dutch Lipid Clinic Network criteria Haase and Goldberg, 2012 Curr Op Lipidology WHO report on FH 1999

13 There s an app for that!

14 GENETICS and CASCADE SCREENING Familial Hypercholesterolemia

15 Genetics of FH Autosomal dominant, > 90% penetrance Prevalence heterozygous FH ~ 1 in 500 Homozygous FH ~ 1 in 1 Million Mutations in 3 genes known to cause FH: LDLR (>1000 variants identified, 80-95% of cases) PCSK9 (< 5% of cases): increased activity leads to degradation of LDLR APOB (5-10% of FH in Northern Europe) Decreased binding of ApoB containing particles to LDLR

16 Genetic mutations that cause FH impair LDL clearance FH is typically caused by mutations in LDLR, Apo B, PCSK9 Apo B: acts as ligand-binding LDL particle to receptor 1:1000 or 10% of FH cases Circulation Liver cell LDL receptor (LDLR): on hepatocyte, binds to Apo B on LDL particle, inducing endocytosis of LDL 1:500 or >85% of mutations PCSK9 enzyme: degrades LDL receptors 1:2500 or <5% of FH cases LDLRAP1 = low-density lipoprotein receptor adaptor protein 1. Image reproduced from: Department of Life Sciences and Institute and Institute of Genome Sciences Web site. Published June 11, Accessed January 19, De Castro-Oros I, et al. Appl Clin Genet. 2010;3: Rader DJ, et al. J Clin Invest. 2003;111: Slide courtesy of NSGC 3. Hopkins PN, et al. J Clin Lipol. 2011;5(3 suppl):s9-s17.

17 Genetic testing is not: Or

18 Genetic testing for FH In the US, the FH usually diagnosed on clinical grounds. Genetic testing can be used in cases where the diagnosis is unclear. Genetic testing is widely used in many countries. Testing generally involves sequencing 3 genes (LDLR, APOB and PCSK9). The yield on genetic testing is ~85% in definite FH cases and ~50% in possible FH. It is probable that this method will be used more widely. May be particularly useful for cascade screening.

19 Whether or not genetic testing is used cascade screening is a MUST! UK screening algorithm NICE guidelines (UK), FH 2008 (Natl Inst. Health and Clin. Ex.)

20 Every family tree is a Family Pre-treatment lipids: TC 327 LDL 265 HDL 51 TG 55

21 If no genetic test results you must use less stringent LDL levels in screening relatives!

22 Dutch experience National lipid and genetic cascade screening program for FH (prevalence 1:400) Set up 1994 So far identified over FH patients First 5 years screened 5442 relatives of 237 FH patients and identified 2039 carriers. Initially only 39% were on meds 2 years after molecular diagnosis 85% on meds Cascade genetic testing is cost effective $8700 per life year gained Work from JJP Kastelein s group Leren, T et al. Comm Genetics 2008

23 CDC has classified FH as a Tier 1 condition FH is a Winnable battle

24 FH Foundation and Registry

25 MANAGEMENT Familial Hypercholesterolemia

26 Management Diet/lifestyle changes important Reduce saturated fat High soluble fiber: 10-20g/day Consider dietician referral Statins are the mainstay of therapy Many will require 2 or more drugs Treat other risk factors (HTN, smoking) DO NOT USE standard risk assessment tools (like Framingham) to estimate risk

27 Goals of therapy FH patients are considered high risk based on NCEP, AHA/ACC, NLA guidelines Rule of thumb to try to cut LDL by 50% Ultimate goal LDL < 100 or even < 70 mg/dl Unlike garden variety HLD non-statin agents like ezetimibe are standard of care Proper therapy can reduce risk of CHD by 80% NCEP ATP Guidelines, Circ 2002.

28 In properly treated FH patients, mortality is similar to the general population Data starting Jan 1, 1990 Just after first statin introduced in the Netherlands Versmissen, J et al. BMJ. 2008

29 Many FH patients cannot get to goal LDL levels with current therapies HeFH Only ~ 20% of patients achieve LDL < 100 mg/dl Only ~ 40% of patients achieve LDL < 130 mg/dl Statin intolerance is a big problem. In clinical practice ~ 10-15% of FH patients are statin intolerant or have significant side effects Majority of HoFH do not have a healthy LDL. Most have disease progression even with apheresis Pijlman et al. Atherosclerosis. 2009

30 LDL apheresis is indicated for HoFH and sometimes for HeFH Apheresis lowers LDL ~80% acutely and ~40% chronically (weekly or biweekly) Indicated if LDL not at goal after 6 mo of diet/meds: HoFH with LDL 300mg/dl HeFH with LDL 300mg/dl plus 0-1 risk factors HeFH with LDL 200mg/dl and 2+ high risk factors HeFH with LDL 160mg/dl very high risk (known CAD) Limited by availability, cost and duration of therapy Usually require weekly sessions, offered ~ 40 centers in US Raal and Santos. Atherosclerosis Horton. J. Lipid. Res. 2009

31 Drug therapies PCSK9 inhibitors Slide adapted from Dan Rader

32 Class Statins Bile Acid Sequestrants Cholesterol Absorption Inhibitor Stanol esters Nicotinic acid LDL apheresis Primary Mechanism of Action (Effects on Lipoprotein Metabolism 1 ) Inhibition of HMG-CoA Reductase ( LDLC clearance via LDL receptors) Bile acid re-absorption ( LDLC clearance via LDL receptors) Intestinal Cholesterol absorption via NPC1L1 ( LDLC clearance via LDL receptors) Intestinal Cholesterol absorption ( LDLC clearance via LDL receptors) Inhibits lipolysis in adipocytes ( VLDL/LDL synthesis; HDLC clearance) Removal of ApoB containing particles ( VLDL, IDL, LDL, RLP) % Reduction in LDL-C HeFH HoFH >35% 2 Up to 28% 3 Usually 10-20% 15% <10% 15% <10% 10% <10% 20% <10% ~40% 4 (up to 75% acutely 5 ) Lomitapide Inhibition of MTP Not indicated ~ 40% Mipomersen ApoB antisense Not indicated ~ 25% Table adapted from Rader DJ, et al. J Clin Invest. 2003;111(12): Stone, NJ and Blum, CB. (2005) Management of Lipids in Clinical Practice. 5 th Ed. 2. Kastelein JJ, et al. N Engl J Med. 2008;358(14); Raal FJ, et al. Atherosclerosis. 2000;150(2): Ito MK, et al. J Clin Lipidol. 2011;5(3 Suppl):S38-S Gordon BR, et al. Am J of Card. 1998;81(4):

33 29 HoFH patients Avg LDL 340mg/dl

34 Mipomersen Antisense to ApoB. Weekly injection Lowers LDL and Lp(a) Raal et al. Lancet 2010

35 Summary FH is a serious cause of morbidity and mortality Prevalence HeFH 1:500 Vastly under diagnosed and treated Suspect FH if untreated LDL > 190 in an adult Take additional family history, look for xanthomas With proper therapy, morbidity is similar to general population Most will require 2 or more drugs Imperative to initiate cascade screening in family members

36 Post-test quiz What is cascade screening? Screening relatives of affected individuals What is the goal LDL for an FH patient? Half or < 100 mg/dl Mutations in 3 genes cause FH, what are they? LRLR, APOB, PCSK9

REPATHA (PCSK9 INHIBITORS)

REPATHA (PCSK9 INHIBITORS) REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as

More information

New Drugs for Lipid Management

New Drugs for Lipid Management New Drugs for Lipid Management John Larry, MD Assistant Professor-Clinical Section Chief, OSU East Cardiovascular Medicine Department of Internal Medicine Division of Cardiovascular Medicine The Ohio State

More information

New Drugs for Lipid Management

New Drugs for Lipid Management New Drugs for Lipid Management John Larry, MD Assistant Professor-Clinical Section Chief, OSU East Cardiovascular Medicine Department of Internal Medicine Division of Cardiovascular Medicine The Ohio State

More information

Evaluating Residual Risk and Long-term Management of the Young CHD Patient. The Arterial Wall

Evaluating Residual Risk and Long-term Management of the Young CHD Patient. The Arterial Wall Evaluating Residual Risk and Long-term Management of the Young CHD Patient Patrick M Moriarty, M.D., Professor of Medicine Director of Clinical Pharmacology, Atherosclerosis and Lipoprotein-apheresis Center

More information

ADMINISTRATIVE POLICY AND PROCEDURE

ADMINISTRATIVE POLICY AND PROCEDURE ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce

More information

Identification and management of familial hypercholesterolaemia (FH) - An overview

Identification and management of familial hypercholesterolaemia (FH) - An overview Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August

More information

DIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO

DIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO DIAGNOSIS AND TREATMENT OF FH CHILDREN O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO DISCLOSURES Kowa MSD Pfizer Astrazeneca Synageva/Alexion OUTLINE Background

More information

Familial hypercholesterolaemia

Familial hypercholesterolaemia Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service

More information

Inhibition of PCSK9: The Birth of a New Therapy

Inhibition of PCSK9: The Birth of a New Therapy Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein

More information

The role of mipomersen therapy in the treatment of familial hypercholesterolemia

The role of mipomersen therapy in the treatment of familial hypercholesterolemia Reviews: Clinical Trial Outcomes The role of mipomersen therapy in the treatment of familial hypercholesterolemia Clin. Invest. (2012) 2(10), 1033 1037 Familial hypercholesterolemia (FH) is a genetic disorder

More information

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date: Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Lipid Metabolism in Familial Hypercholesterolemia

Lipid Metabolism in Familial Hypercholesterolemia Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis

More information

Juxtapid (lomitapide)

Juxtapid (lomitapide) Juxtapid (lomitapide) Policy Number: 5.01.599 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Juxtapid

More information

Familial Hypercholeterolaemia

Familial Hypercholeterolaemia Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,

More information

Distinguishing FH from non-fh: Right therapy, right patient, right time. Joshua W. Knowles, MD, PhD Stanford and the FH Foundation

Distinguishing FH from non-fh: Right therapy, right patient, right time. Joshua W. Knowles, MD, PhD Stanford and the FH Foundation Distinguishing FH from non-fh: Right therapy, right patient, right time Joshua W. Knowles, MD, PhD Stanford and the FH Foundation Disclosures Role as CMA of the FH Foundation is not compensated. www.thefhfoundation.org

More information

B. Patient has not reached the percentage reduction goal with statin therapy

B. Patient has not reached the percentage reduction goal with statin therapy Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

More information

Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics

Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics Review Article Endocrinol Metab 2017;32:36-40 https://doi.org/10.3803/enm.2017.32.1.36 pissn 2093-596X eissn 2093-5978 Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel

More information

Familial Hypercholesterolemia What a cardiologist should know

Familial Hypercholesterolemia What a cardiologist should know Institut für Klinische Chemie Arnold von Eckardstein Familial Hypercholesterolemia What a cardiologist should know Etiology of Hypercholesterolemia monogenic: (rare): e.g. familial hypercholesterolemia

More information

Presenter Disclosure Information

Presenter Disclosure Information 1:45 2:45pm Lipid Management: A Primary Care Perspective Presenter Disclosure Information The following relationships exist related to this presentation: Richard F. Wright, MD, FACC, has no financial relationships

More information

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form  Submit request via: Fax Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density

More information

Genetic considerations in the treatment of familial hypercholesterolemia

Genetic considerations in the treatment of familial hypercholesterolemia Clinical Lipidology ISSN: 1758-4299 (Print) 1758-4302 (Online) Journal homepage: https://www.tandfonline.com/loi/tlip20 Genetic considerations in the treatment of familial hypercholesterolemia Ann M Moyer

More information

Cascade Screening for FH: the U.S. experience

Cascade Screening for FH: the U.S. experience Cascade Screening for FH: the U.S. experience Paul N. Hopkins, MD, MSPH Professor of Internal Medicine Cardiovascular Genetics University of Utah Disclosures Consultant Genzyme, Amgen, Regeneron Research

More information

The Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia

The Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia The Addition of Ezetimibe to Statin therapy in Patients with Homozygous Familial Hypercholesterolaemia Submitted in fulfilment with the requirements for the degree Master in Medicine (MMed) Dr Adriano

More information

Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary

Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization

More information

This policy addresses the use of Juxtapid (lomitapide) for the treatment of treatment of homozygous familial hypercholesterolemia.

This policy addresses the use of Juxtapid (lomitapide) for the treatment of treatment of homozygous familial hypercholesterolemia. Subject: Juxtapid (lomitapide) Original Effective Date: 10/30/2013 Policy Number: MCP-155 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Medical Policy is intended to

More information

UNIVERSITA DI PISA CHIMICA E TECNOLOGIE FARMACEUTICHE FAMILIAL HYPERCHOLESTEROLEMIA DIPARTIMENTO DI FARMACIA GENETIC CAUSES AND THERAPY

UNIVERSITA DI PISA CHIMICA E TECNOLOGIE FARMACEUTICHE FAMILIAL HYPERCHOLESTEROLEMIA DIPARTIMENTO DI FARMACIA GENETIC CAUSES AND THERAPY UNIVERSITA DI PISA DIPARTIMENTO DI FARMACIA CHIMICA E TECNOLOGIE FARMACEUTICHE CORSO DI BASI BIOCHIMICHE DELL AZIONE DEI FARMACI FAMILIAL HYPERCHOLESTEROLEMIA GENETIC CAUSES AND THERAPY ERIKA ROSARIA PACCIOLLA

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

Cost effectiveness of cascade testing for FH:

Cost effectiveness of cascade testing for FH: Cost effectiveness of cascade testing for FH: Background In 2008, NICE published evidence-based guidelines for identification and management of FH Updated 2017 Recommended all Clinical FH DNA test to confirm

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this

More information

Lipid Lowering in Patients at High Risk for Cardiovascular Disease

Lipid Lowering in Patients at High Risk for Cardiovascular Disease Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel

More information

PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia

PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;

More information

PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab)

PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab) PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the

More information

PCSK9 Inhibitors: Promise or Pitfall?

PCSK9 Inhibitors: Promise or Pitfall? PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential

More information

Familial Hypercholesterolemia

Familial Hypercholesterolemia Familial Hypercholesterolemia Dr.Ramzi Al-Mohammadi Assistant Professor of Medicine Interventional Cardiologist, Advanced HF and Transplant Consultant Classification of Hyperlipedemia Primary hyperlipedemia:

More information

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia

More information

HoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients

HoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients HoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients Claudia Stefanutti Department of Molecular Medicine, Sapienza University Rome, Italy HoFH, homozygous familial

More information

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date: Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.

More information

Drug Prior Authorization Guideline PCSK9 Inhibitors -

Drug Prior Authorization Guideline PCSK9 Inhibitors - Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional

More information

Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia

Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia The Cardiac Society of Australia and New Zealand Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia This guideline was originally developed by David Sullivan, Gerard Watts, Ian

More information

Juxtapid and Kynamro

Juxtapid and Kynamro DRUG POLICY Juxtapid and Kynamro BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions

More information

Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus

Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University

More information

Juxtapid. Juxtapid (lomitapide) Description

Juxtapid. Juxtapid (lomitapide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Juxtapid Page: 1 of 6 Last Review Date: September 20, 2018 Juxtapid Description Juxtapid (lomitapide)

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)

More information

WORKSHOP 1. Management of Patients with Familial Hypercholesterolemia

WORKSHOP 1. Management of Patients with Familial Hypercholesterolemia WORKSHOP 1 Management of Patients with Familial Hypercholesterolemia Tutors: Manal Al-Kindi (Oman)/ Gilles Lambert (France) (Case 1) Zuhier Awan (KSA)/ Raul Santos (Brazil) (Case 2) Khalid Al-Waili (Oman)/

More information

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

PCSK9 inhibition across a wide spectrum of patients: One size fits all? PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl

More information

LDL Apheresis: Familial Hypercholesterolemia

LDL Apheresis: Familial Hypercholesterolemia LDL Apheresis: Familial Hypercholesterolemia Joyce L Ross, MSN, CRNP, CCS, FNLA, FPCNA Certified Clinical Specialist, Diplomat ACCL Past President PCNA Immediate Past President National Lipid Association

More information

Very high cholesterol from birth: are target LDL cholesterol levels now achievable with new treatments?

Very high cholesterol from birth: are target LDL cholesterol levels now achievable with new treatments? Press release 3 Madrid, May 3 st, 204 82 nd Annual Congress of the European Atherosclerosis Society (EAS) May 3-June 3, Madrid, Spain Very high cholesterol from birth: are target LDL cholesterol levels

More information

Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17

Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy

More information

From Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th. Dr. Gilles Lambert

From Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th. Dr. Gilles Lambert Dr. Gilles Lambert Associate Professor in Cell Biology University of Nantes Medical School Group Leader, Laboratory of Nutrition and Metabolism, University Hospital of Nantes From Biology to Therapy The

More information

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The, LDL Uptake, and the Free Cholesterol Pool I. Michael Brown and Joseph Goldstein A. Studied families with familial hypercholesterolemia. B. Defined the relationship

More information

If yes, continue to #2. If no, do not approve. DENIAL TEXT: See the initial denial text at the end of the guideline.

If yes, continue to #2. If no, do not approve. DENIAL TEXT: See the initial denial text at the end of the guideline. Generic Brand HICL GCN Exception/Other LOMITAPIDE JUXTAPID 39883 This drug requires a written request for prior authorization. All requests for Juxtapid (lomitapide) require review by a pharmacist prior

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject PCSK9 Inhibitors Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 9 References... 9 Effective Date... 01/15/2018

More information

STATIN UTILIZATION MANAGEMENT CRITERIA

STATIN UTILIZATION MANAGEMENT CRITERIA STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,

More information

Kynamro. Kynamro (mipomersen) Description

Kynamro. Kynamro (mipomersen) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro

More information

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia

More information

10/1/2008. Therapy? Disclosure Statement

10/1/2008. Therapy? Disclosure Statement What s New in Lipid Therapy? Brooke Hudspeth, PharmD Diabetes Care Kroger Pharmacy Disclosure Statement In accordance with policies set forth by the Accreditation Council for Continuing Medical Education

More information

High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.

High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal

More information

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Learning Objectives

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Learning Objectives Learning Objectives Utilize evidence-based lipoprotein management strategies for non-ldl-c lipid targets Describe the risk factors, disease spectrum, and appropriate management of familial hypercholesterolemia

More information

Kynamro. Kynamro (mipomersen) Description

Kynamro. Kynamro (mipomersen) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)

More information

Medication Policy Manual Policy No: Topic: Date of Origin: Committee Approval Date: Next Review Date: Effective Date: IMPORTANT REMINDER Description

Medication Policy Manual Policy No: Topic: Date of Origin: Committee Approval Date: Next Review Date: Effective Date: IMPORTANT REMINDER Description Medication Policy Manual Policy No: dru301 Topic: Kynamro, mipomersen Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT

More information

Lipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels

Lipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels Lipoprotein Formation, Structure and Metabolism: Balance and the Regulation of Plasma Lipid Levels David E. Cohen, MD, PhD Director of Hepatology, Gastroenterology Division, Brigham and Women s Hospital

More information

Familial Hypercholesterolemia

Familial Hypercholesterolemia Understanding (FH) Familial Hypercholesterolemia For more information, visit Understanding Familial Hypercholesterolemia (FH) Your doctor may have told you that too much of the bad type of cholesterol

More information

PCSK9 Inhibition: From Genetics to Patients

PCSK9 Inhibition: From Genetics to Patients PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research

More information

Nephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler

Nephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9- Inhibitors, Lipoprotein Apheresis or

More information

UPDATES IN LIPID MANAGEMENT

UPDATES IN LIPID MANAGEMENT UPDATES IN LIPID 2017 Cardiovascular Symposium MANAGEMENT SUDHA RAVILLA, MD, DIPLOMATE, ABCL MEDICAL DIRECTOR CLINICAL LIPIDOLOGY TMHPP METABOLIC HEALTH CENTER INTRODUCTION CVD is STILL the No. 1 cause

More information

Medication Policy Manual. Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013

Medication Policy Manual. Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013 Medication Policy Manual Policy No: dru302 Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)

More information

Appendix F Simon Broome Diagnostic criteria for index individuals and relatives

Appendix F Simon Broome Diagnostic criteria for index individuals and relatives Appendix F Simon Broome Diagnostic criteria for index individuals and relatives 1 SIMON BROOME DIAGNOSTIC CRITERIA FOR INDEX INDIVIDUALS (PROBANDS) 2 2 GENDER- AND AGE-SPECIFIC LDL-C CRITERIA FOR THE DIAGNOSIS

More information

Advances in Lipid Management

Advances in Lipid Management Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center

More information

Lipid metabolism in familial hypercholesterolemia

Lipid metabolism in familial hypercholesterolemia Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha

More information

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center

More information

Kynamro (mipomersen)

Kynamro (mipomersen) Kynamro (mipomersen) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201803/01/2019 POLICY A. INDICATIONS The indications below including

More information

Treatment of Atherosclerosis in 2007

Treatment of Atherosclerosis in 2007 Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines PCSK9 Inhibitors: Praluent TM, Repatha TM Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 10/9/15

More information

Cholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors

Cholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors USC-April 21, 2018, Los Angeles Cholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors P.K.Shah, MD, MACC Shapell and Webb Chair in Clinical Cardiology, Director,

More information

The new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice

The new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice ... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol

More information

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Dyslipidemia Objectives: Not given. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Team Leader: Amal Alshaibi Revised By: Yara Aldigi and Basel almeflh Resources: 435

More information

PCSK9 inhibition in homozygous familial hypercholesterolaemia

PCSK9 inhibition in homozygous familial hypercholesterolaemia PCSK9 inhibition in homozygous familial hypercholesterolaemia Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis Research Center

More information

Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam

Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded

More information

Familial Hypercholesterolemia New treatments

Familial Hypercholesterolemia New treatments Familial Hypercholesterolemia New treatments Prof. Shlomo Keidar Head Internal Medicine A Rambam Health Care Campus IAS, Haifa May 2013 Effect of treatment on CV survival in Familial Hypercholesterolemia

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors

Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention

More information

LIPID CLUB Rome, 2014

LIPID CLUB Rome, 2014 LIPID CLUB Rome, 2014 June the 6h 6th Hyperlipidaemia in FH Children Ornella Guardamagna University of Torino DICLOSURES Medpace Kowa DSMB member MSD, Pfizer, Synageva Investigator in industry funded trials

More information